Perrigo has announced an agreement to divest its OTC businesses in Brazil and Mexico to private equity firm Advent International as part of Perrigo’s efforts to improve its profit margins. The deal – for which financial details were not disclosed – is expected to close in the second half of 2021, subject to approval from Mexico’s Federal Commission of Economic Competition.
Perrigo Divests In Brazil And Mexico
Advent International Picks Up OTC Businesses In Latin America
Perrigo has revealed plans to divest its OTC businesses in Brazil and Mexico to private equity firm Advent International, citing insufficient scale and weak margins.
More from Deals
• By
Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.
• By
The move adds another compound with the coveted 180-day exclusivity to Hikma’s portfolio for an undisclosed sum.
• By
After announcing the agreement last month, Xbrane has now approved its deal with Alvotech as part of an extra general meeting.
• By
With six biosimilars reportedly in development, Polpharma Biologics has linked up with Chinese CDMO Chime Biologics, looking to tap its “all-in-one solutions to accelerate biosimilar development and reduce the time-to-market” for an undisclosed biosimilar product.
More from Business
• By
Despite industry-wide uncertainty surrounding the Trump administration’s interest in pharma-focused tariffs, Hikma has maintained its guidance for the 2025 financial year.
• By
With the Global Generics & Biosimilars Awards 2025 taking place in Frankfurt this October, we bring you five key pieces of guidance to help ensure that your entries stand out from the competition.
• By
Denosumab competition is heating up in Europe, with four more companies this month gaining EMA endorsements for their Prolia and Xgeva biosimilar rivals.